Predictive value of MRI combined with serum lncRNA KCNQ1OT1， miR-204-5p for axillary lymph node metastasis of breast cancer

doi:10.3760/cma.j.cn371439-20240727-00013

Abstract

Abstract:

Objective To investigate the value of MRI combined with serum long non-coding RNA （lncRNA） KCNQ1OT1 and microRNA-204-5p （miR-204-5p） in predicting axillary lymph node metastasis in breast cancer patients. Methods A total of 70 patients with breast cancer who were surgically diagnosed in the No.2 Hospital of Baoding， Hebei Province from January 2020 to December 2022 were selected as the study objects. Patients were divided into metastatic group （n=31） and non-metastatic group （n=39） according to the status of lymph node metastasis. The MRI features and the levels of serum lncRNA KCNQ1OT1 and miR-204-5p were compared between the two groups. Receiver operator characteristic （ROC） curve was used to evaluate the predictive efficacy of the three detections alone and in combination for axillary lymph node metastasis in breast cancer. Results There were statistically significant differences in tumor maximum diameter （χ²=4.28， P=0.039） and Ki-67 expression （χ²=10.88， P=0.001） between the metastatic and non-metastatic groups. There were statistically significant differences between the breast cancer axillary lymph node metastatic group and the non-metastatic group in the mode of internal reinforcement type （χ²=6.60，P=0.037）， peripheral vessel diameter（t=4.33，P<0.001）， number of peripheral vessel roots（t=4.38，P<0.001）， apparent diffusion coefficient（t=3.59，P=0.001）， and MRI lymph node status（χ²=29.70，P<0.001）. The level of serum lncRNA KCNQ1OT1 in metastatic group was higher than that in non-metastatic group （1.41±0.32 vs. 0.99±0.18， t=6.94， P<0.001）， and the level of miR-204-5p was lower than that in non-metastatic group （0.72±0.17 vs. 1.03±0.21， t=6.66， P<0.001）. Bioinformatics analysis showed that miR-204-5p may have a targeting relationship with lncRNA KCNQ1OT1. ROC curve analysis showed the area under the curve of MRI features， serum levels of lncRNA KCNQ1OT1， miR-204-5p and their combined detection to predict lymph node metastasis of breast cancer patients were 0.823， 0.858， 0.843， 0.946， respectively. The predictive efficacy of the combined detection was better than that of MRI features and serum lncRNA KCNQ1OT1 and miR-204-5p levels alone （Z=3.29， P=0.001； Z=2.07， P=0.038； Z=2.23， P=0.026）. Conclusions Serum lncRNA KCNQ1OT1 level is up-regulated and the level of miR-204-5p is down-regulated in patients with axillary lymph node metastasis of breast cancer. And the combination of MRI features with serum lncRNA KCNQ1OT1 and miR-204-5p has high predictive efficacy in predicting lymph node metastasis in breast cancer patients.

Key words: Breast neoplasms, Neoplasm metastasis, Magnetic resonance imaging, Long non-coding RNA, KCNQ1OT1, miR-204-5p

Wang Zhibao, Li Guangxian, Zhang Xinxin, Cui Wei, Zhang Wei. Predictive value of MRI combined with serum lncRNA KCNQ1OT1， miR-204-5p for axillary lymph node metastasis of breast cancer[J]. Journal of International Oncology, 2025, 52(2): 89-93.

Figures/Tables 6

References 14

[1]	Sharon CE, Wang M, Tortorello GN, et al. Impact of patient comorbidities on presentation stage of breast and colon cancers[J]. Ann Surg Oncol, 2023, 30(8): 4617-4626. DOI: 10.1245/s10434-023-13596-z. pmid: 37208570
[2]	Marino MA, Avendano D, Zapata P, et al. Lymph node imaging in patients with primary breast cancer: concurrent diagnostic tools[J]. Oncologist, 2020, 25(2): e231-e242. DOI: 10.1634/theoncologist.2019-0427.
[3]	Cashmore MT, McCann AJ, Wastling SJ, et al. Clinical quantitative MRI and the need for metrology[J]. Br J Radiol, 2021, 94(1120): 20201215. DOI: 10.1259/bjr.20201215.
[4]	Liu G, Shi L, Wang B, et al. Role of oncogenic long noncoding RNA KCNQ1OT1 in colon cancer[J]. Oncol Res, 2024, 32(3): 585-596. DOI: 10.32604/or.2023.029349. pmid: 38361755
[5]	Zhang P, Hou Q, Yue Q. MiR-204-5p/TFAP2A feedback loop positively regulates the proliferation, migration, invasion and EMT process in cervical cancer[J]. Cancer Biomark, 2020, 28(3): 381-390. DOI: 10.3233/CBM-191064. pmid: 32474464
[6]	中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2015版)[J]. 中国癌症杂志, 2015, 25(9): 692-754. DOI: 10.3969/j.issn.1007-3969.2015.09.010.
[7]	戴兴伟, 申云霞, 黄奕巧, 等. 多参数MRI联合免疫炎症指标预测乳腺癌腋窝淋巴结转移的价值研究[J]. 磁共振成像, 2022, 13(7): 116-120, 128.
[8]	Balla A, Weaver DL. Pathologic evaluation of lymph nodes in breast cancer: contemporary approaches and clinical implications[J]. Surg Pathol Clin, 2022, 15(1): 15-27. DOI: 10.1016/j.path.2021.11.002. pmid: 35236631
[9]	Chang JM, Leung JWT, Moy L, et al. Axillary nodal evaluation in breast cancer: state of the art[J]. Radiology, 2020, 295(3): 500-515. DOI: 10.1148/radiol.2020192534. pmid: 32315268
[10]	孟繁明. 伊尼妥单抗联合卡培他滨治疗曲妥珠单抗经治的HER2阳性晚期乳腺癌1例[J]. 国际肿瘤学杂志, 2024, 51(8): 538-541. DOI: 10.3760/cma.j.cn371439-20231130-00090.
[11]	Wang MF, Xu W, Qin T. The differential diagnosis of benign and malignant breast tumors with MRI quantitative and semi-quantitative parameters and the correlation analysis with biological indicators of breast cancer[J]. Chin J Magn Reson Imaging, 2020, 11(12): 1174-1177. DOI: 10.12015/issn.1674-8034.2020.12.021.
[12]	Yu Y, Tan Y, Xie C, et al. Development and validation of a pre-operative magnetic resonance imaging radiomics-based signature to predict axillary lymph node metastasis and disease-free survival in patients with early-stage breast cancer[J]. JAMA Netw Open, 2020, 3(12): e2028086. DOI: 10.1001/jamanetworkopen.2020.28086.
[13]	Sun H, Li Y, Kong H, et al. Dysregulation of KCNQ1OT1 promotes cholangiocarcinoma progression via miR-140-5p/SOX4 axis[J]. Arch Biochem Biophys, 2018, 658: 7-15. DOI: 10.1016/j.abb.2018.09.019. pmid: 30243712
[14]	Zhang M, Bai X, Zeng X, et al. CircRNA-miRNA-mRNA in breast cancer[J]. Clin Chim Acta, 2021, 523: 120-130. DOI: 10.1016/j.cca.2021.09.013. pmid: 34537217

临床资料	转移组（n=31）	未转移组（n=39）	t/χ²值	P值	临床资料	转移组（n=31）	未转移组（n=39）	t/χ²值	P值
年龄（岁）	44.90±8.52	45.56±8.97	0.31	0.756	雌激素受体状态
体质量指数（kg/m²）	23.56±2.48	23.98±2.65	0.68	0.500	阳性	17（54.84）	16（41.03）	1.32	0.250
绝经状态					阴性	14（45.16）	23（58.97）	1.32	0.250
已绝经	15（48.39）	18（46.15）	0.04	0.853	孕激素受体状态
未绝经	16（51.61）	21（53.85）	0.04	0.853	阳性	18（58.06）	14（35.90）	3.42	0.064
肿瘤最大径（cm）					阴性	13（41.94）	25（64.10）	3.42	0.064
≤2	13（41.94）	26（66.67）	4.28	0.039	人表皮生长因子受体2状态
>2	18（58.06）	13（33.33）	4.28	0.039	阳性	16（51.61）	13（33.33）	2.38	0.123
组织分级					阴性	15（48.39）	26（66.67）	2.38	0.123
Ⅰ级	7（22.58）	16（41.03）	4.42	0.110	Ki-67表达
Ⅱ级	10（32.26）	14（35.90）			低表达	10（32.26）	28（71.79）	10.88	0.001
Ⅲ级	14（45.16）	9（23.07）			高表达	21（67.74）	11（28.21）	10.88	0.001

项目	转移组（n=31）	未转移组（n=39）	χ²/t值	P值
内部强化类型
均匀	3（9.68）	9（23.08）	6.60	0.037
不均匀	11（35.48）	20（51.28）
边缘强化	17（54.84）	10（25.64）
周围血管管径（mm）	3.39±0.82	2.63±0.65	4.33	<0.001
周围血管根数（根）	6.96±2.28	4.89±1.67	4.38	<0.001
强化峰值（PV）	376.59±112.87	329.86±90.29	1.93	0.058
T2相对信号强度	2.81±0.86	2.56±0.63	1.40	0.165
早期强化率（%）	1.79±0.43	1.65±0.31	1.58	0.118
表观扩散系数（×10^-6 mm²/s）	823.58±126.93	965.37±188.69	3.59	0.001
MRI淋巴结状态
阴性	7（22.58）	34（87.18）	29.70	<0.001
阳性	24（77.42）	5（13.82）	29.70	<0.001

项目	AUC	截断值	敏感性（%）	特异性（%）	95%CI	约登指数
MRI特征	0.823		77.42	87.18	0.716~0.904	0.646
lncRNA KCNQ1OT1	0.858	1.22	74.19	94.87	0.754~0.930	0.691
miR-204-5p	0.843	0.90	83.87	74.36	0.737~0.919	0.582
三者联合	0.946		93.55	84.62	0.865~0.986	0.782

[1]	Wang Yi, Wang Qiangli, Zhang Jia, Yang Yijin, Wang Sheng. Relationship between the expression of SUCNR1 and YBX1 in tissues of patients with colorectal cancer liver metastases and their clinicopathological characteristics and prognosis [J]. Journal of International Oncology, 2025, 52(3): 152-157.
[2]	Han Xiaoxu, Zhang Nan, Liu Shuai. Progress in the study of the pregnane X receptor in drug resistance in breast cancer [J]. Journal of International Oncology, 2024, 51(9): 590-594.
[3]	Zhao Biao, Pu Qin, Yuan Meifang, Ma Lishuang, Li Han, Yang Yi, Sun Chaoxi. Dosimetric study of intensity-modulated radiotherapy and volumetric intensity modulated arc therapy based on the inner edge tangent field for radiotherapy after breast-conserving surgery of left-sided breast cancer [J]. Journal of International Oncology, 2024, 51(7): 441-447.
[4]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[5]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[6]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[7]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[8]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[9]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[10]	Tan Shuangxiu, Zhang Yidan, Wang Ying, Yu Pengli, Kong Wentao, Yao Jing, Chen Qiaoliang. Value of conventional ultrasound combined with shear wave elastography in differentiating non-mass ductal carcinoma in situ from invasive breast cancer [J]. Journal of International Oncology, 2024, 51(12): 743-748.
[11]	Wang Li, Xiao Han, Huang Guofu. Mechanism of action and clinical significance of circular RNA in triple negative breast cancer [J]. Journal of International Oncology, 2024, 51(12): 774-778.
[12]	Zhou Mingrui, Qi Mengqi, Zhang Yanyan, Shi Yinuan, Yue Chuan, Zhang Yan, Liu Xianqiang, Zhang Yan. Research progress in the relationship between microbial communities and breast cancer in human tissues [J]. Journal of International Oncology, 2024, 51(12): 779-784.
[13]	Yu Degang, Jia Junmei. Research progress in the treatment of bone metastasis in lung cancer [J]. Journal of International Oncology, 2024, 51(12): 789-793.
[14]	Zhu Bin, Wan Tao, Xu Hua, Jia Hao, Chen Shixin. Value analysis of the prediction model based on multimodal MRI characteristics for the differential diagnosis of benign and malignant BI-RADS 4 types of breast tumors [J]. Journal of International Oncology, 2024, 51(11): 678-683.
[15]	Luo Yijun, Yao Weirong, Wang Xiaoli. Targeted therapeutic progression of EGFR mutation in non-small cell lung cancer with brain metastasis [J]. Journal of International Oncology, 2024, 51(11): 717-722.